THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.16] ID: TIP-MED-000060 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Insulin Lispro (Rapid-Acting & Biphasic Premixed 25/75 or 50/50)

Active Ingredient / Scientific Identity: Insulin Lispro • Class: Rapid-Acting Recombinant Human Insulin Analogue (B28 Lysine and B29 Proline Inverted)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Insulin Lispro (Rapid-Acting & Biphasic Premixed 25/75 or 50/50) ([4.16] | ID: TIP-MED-000060) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/4-16-insulin-lispro-rapid-acting-biphasic-premixed-25-75-or-50-50/
Generic / Entity NameInsulin Lispro (Rapid-Acting & Biphasic Premixed 25/75 or 50/50) ([4.16])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassRapid-Acting Recombinant Human Insulin Analogue (B28 Lysine and B29 Proline Inverted)
Available Dosage FormsPrefilled KwikPen (3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100) (also U-200 KwikPen in selec
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal & Hepatic: Insulin requirements decrease in moderate-to-severe CKD (eGFR <45 mL/min) and hepatic insufficiency; titrate
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Insulin Lispro (Rapid-Acting & Biphasic Premixed 25/75 or 50/50) (TIP-MED-000060, Reference Code [4.16]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Rapid-Acting Recombinant Human Insulin Analogue (B28 Lysine and B29 Proline Inverted). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.16], p. 52): Rapid-Acting (Clear): Humalog (Eli Lilly), Eglucent (Biocon); Biphasic Premixed (Cloudy): Humalog Mix 25 (25% Lispro + 75% Lispro Protamine), Humalog Mix 50 (50% Lispro + 50% Lispro Protamine) — Strengths & Dosage Forms: Prefilled KwikPen (3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100) (also U-200 KwikPen in select markets)
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.16], p. 52): Rapid-Acting (Clear): Humalog (Eli Lilly), Eglucent (Biocon); Biphasic Premixed (Cloudy): Humalog Mix 25 (25% Lispro + 75% Lispro Protamine), Humalog Mix 50 (50% Lispro + 50% Lispro Protamine) — Strengths & Dosage Forms: Prefilled KwikPen (3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100) (also U-200 KwikPen in select markets)
Dosage Forms & Available Strengths:
Prefilled KwikPen (3 mL), Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100) (also U-200 KwikPen in select markets)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Rapid-Acting Recombinant Human Insulin Analogue (B28 Lysine and B29 Proline Inverted) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Rapid-Acting Recombinant Human Insulin Analogue (B28 Lysine and B29 Proline Inverted) for Mealtime glycaemic control in Type 1 and Type 2 diabetes mellitus (Humalog); twice-daily premixed therapy (Humalog Mix 25 / Mix 50)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Mealtime glycaemic control in Type 1 and Type 2 diabetes mellitus (Humalog)
  • twice-daily premixed therapy (Humalog Mix 25 / Mix 50)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Individualised subcutaneously per patient blood glucose and meal schedule. Pharmacokinetic Profile: Onset 10–15 min, Peak 30–90 min, Duration 3–5 hours (Humalog Clear) or 16–24 hours (Humalog Mix 25/50).

Administration & Meal Timing: Inject within 15 minutes BEFORE starting a meal, or immediately after a meal (never wait 30 minutes before eating). | Humalog: With 1 to 3 main meals daily (paired with basal insulin). Humalog Mix 25/50: Twice daily with breakfast and dinner.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal & Hepatic: Insulin requirements decrease in moderate-to-severe CKD (eGFR <45 mL/min) and hepatic insufficiency; titrate carefully using SMBG.
Elimination & Renal Adjustment:
Renal & Hepatic: Insulin requirements decrease in moderate-to-severe CKD (eGFR <45 mL/min) and hepatic insufficiency; titrate carefully using SMBG.
Hepatic Impairment Considerations:
Renal & Hepatic: Insulin requirements decrease in moderate-to-severe CKD (eGFR <45 mL/min) and hepatic insufficiency; titrate carefully using SMBG.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated during hypoglycaemia. Humalog Mix 25 and Mix 50 (cloudy protamine suspensions) must never be administered intravenously. Do not confuse Humalog Mix 25 with Humalog Mix 50 (Mix 50 has double the rapid-acting component for patients with high carbohydrate meals).

Key Clinical Precautions: Renal & Hepatic: Insulin requirements decrease in moderate-to-severe CKD (eGFR <45 mL/min) and hepatic insufficiency; titrate carefully using SMBG.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hypoglycaemia (within 1–3 hours post-injection if meal is small or delayed), lipohypertrophy, weight gain.
  • Severe hypoglycaemia, hypokalaemia, generalised allergic reaction.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Same as Insulin Aspart and Human Insulin (beta-blockers mask warning signs; alcohol, ACEIs, and secretagogues potentiate hypoglycaemia; steroids antagonise effect)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Ensure the patient eats within 10–15 minutes of injection. For Humalog Mix 25 or Mix 50, gently roll and invert the pen 10 times until uniformly cloudy before attaching the pen needle. Prime the pen with 2 units before each injection, hold the thumb button for 10 seconds inside the skin, and remove the needle immediately after injection to prevent air entry or leakage.
  • Meal & Clock Timing Instruction: Inject within 15 minutes BEFORE starting a meal, or immediately after a meal (never wait 30 minutes before eating). (Humalog: With 1 to 3 main meals daily (paired with basal insulin). Humalog Mix 25/50: Twice daily with breakfast and dinner.)
  • Missed Dose Protocol: If forgotten before eating, Humalog may be injected immediately after the meal. Never double the next meal's dose.
  • Geriatric Dispensing Pearl: Verify whether the patient is using Humalog (Clear), Humalog Mix 25, or Humalog Mix 50, and confirm they have a working glucometer and glucose packets at home.

Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.16] (p. 52)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/4-16-insulin-lispro-rapid-acting-biphasic-premixed-25-75-or-50-50/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.